Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ledipasvir/Sofosbuvir +/- Ribavirin in HCV Patients Who Failed Prior Sofosbuvir
NCT02600351Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ledipasvir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Nov 2015; status: terminated.
02
Drugs
ledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02600351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02600351.